Downstream Processing

Pic:getty/markrubens

WuXi Biologics to build CRDMO center in Singapore

By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

pic:getty/zulotukhin

Flow Eighteen38 to double protein purification capacity

By Rachel Arthur

Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, has announced a €5m ($5.58m) investment into its protein production and biophysical characterization capabilities...

© GettyImages/Olena_T

Cryoport and Cell Matters team up on cryopreservation services

By Jane Byrne

Cryoport, Inc. has entered into a partnership with specialized Belgian CDMO, Cell Matters, to deliver end-to-end cryopreservation services for leukapheresis derived therapies supporting both autologous and allogeneic cell therapies.

© GettyImages/Monty Rakusen

Lonza and Doer Biologics in expression system license deal

By Jane Byrne

Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.

Sartolab filtration units

Sartorius launches redesigned filtration unit

By Ben Hargreaves

The vacuum filtration units are suitable for lab-based research in low volumes, with the company stating the update improves speed, capacity, and stability.

Pic:getty/adamgault

Biovac to manufacture Pfizer COVID-19 doses in Africa

By Rachel Arthur

South African biopharmaceutical company The Biovac Institute will manufacture and distribute Pfizer and BioNTech’s COVID-19 vaccine in Africa, with the three companies signing a letter of intent this week.

© GettyImages/Isaac74

Coriolis expands ATMP facilities to advance formulation

By Ben Hargreaves

Coriolis Pharma has announced a 7,800-meter-square expansion to a building situated in Munich, Germany, where the company is headquartered, that will host formulation development for advanced therapeutic medicine products (ATMPs).